Evaluation of hypoglycemic potential of Cuminum cyminum and its role in modulation of cognitive function in rats with induced diabetes

Abhishek  Kumar; Amit Shekhar; Mitali Dua; Indu Jangra; Umesh Suranagi; Ekta Arora

doi:10.69857/joapr.v12i6.549

Authors

Abhishek Kumar Satyawadi Raja Harishchandra Hospital (SRHC), Narela, Delhi Government Health Services, Delhi- 110040, India
Amit Shekhar Department of Dermatology, Moti Lal Nehru Medical College, Prayagraj-211002, India
Mitali Dua Baba Saheb Ambedkar Hospital, Rohini, Delhi-110085, India
Indu Jangra Department of Pharmacology, Government Institute of Medical Sciences (GIMS), Greater Noida-201310, India
Umesh Suranagi Department of Pharmacology, Lady Harding Medical College (LHMC), New Delhi-110001, India
Ekta Arora Department of Pharmacology, Government Institute of Medical Sciences (GIMS), Greater Noida-201310, India

DOI:

https://doi.org/10.69857/joapr.v12i6.549

Keywords:

Acetylcholinesterase, Cognition, Cuminum Cyminum, Diabetes mellitus, Sulbutiamine, Resveratrol

Abstract

Background: This study investigated the effects of Cuminum cyminum (C. cyminum) on cognitive behaviour and acetylcholinesterase (AChE) levels in diabetic rats, comparing its efficacy with Glibenclamide, Sulbutiamine, and Resveratrol.

Methods: Wistar rats were randomized into 12 groups (n=10) half diabetic and half non-diabetic controls and administered C. cyminum 500 mg/kg and 1000 mg/kg, Glibenclamide (5 mg/kg), Sulbutiamine (50 mg/kg), and Resveratrol (25 mg/kg). Controls included diabetic and non-diabetic rats without treatment. Blood glucose, insulin, oxidative stress markers, and AChE levels were measured, along with behavioural parameters of learning and memory using the elevated plus maze, passive avoidance, and Morris water maze.

Results: Both doses of C. cyminum significantly reduced blood glucose levels (Dose I decreased blood glucose levels from 278.5 ± 3.66 mg/dl to 136.8 ± 4.91 mg/dl while dose II decreased the blood glucose levels to 138.8 ± 3.83 mg/dl) and improved learning and memory, as evidenced by faster transfer latency (TL) and better retention in the elevated plus maze and Morris water maze. The higher dose was particularly effective in reducing brain AChE levels and improving cognitive performance in passive avoidance tests.

Conclusion: Both doses of C. cyminum decreased the AChE activity induced by diabetes, improving learning and memory. The antioxidant and anti-hyperglycaemic potential may partially contribute to delaying cognitive impairment. Thus, the study suggests that C. cyminum may be beneficial in mitigating behavioural and biochemical changes associated with diabetes mellitus, offering potential as a complementary therapy to existing diabetes treatments. Elaborate studies in the future are essential to explore its antidiabetic and neuroprotective potential.

Downloads

Download data is not yet available.

References

Antar SA, Ashour NA, Sharaky M, Khattab M, Ashour NA, Zaid RT, Roh EJ, Elkamhawy A, Al-Karmalawy AA. Diabetes mellitus: Classification, mediators, and complications; A gate to identify potential targets for the development of new effective treatments. Biomedicine & Pharmacotherapy, 168, 115734 (2023) https://doi.org/https://doi.org/10.1016/j.biopha.2023.115734.

Chan JCN, Lim L-L, Wareham NJ, Shaw JE, Orchard TJ, Zhang P, Lau ESH, Eliasson B, Kong APS, Ezzati M, Aguilar-Salinas CA, McGill M, Levitt NS, Ning G, So W-Y, Adams J, Bracco P, Forouhi NG, Gregory GA, Guo J, Hua X, Klatman EL, Magliano DJ, Ng B-P, Ogilvie D, Panter J, Pavkov M, Shao H, Unwin N, White M, Wou C, Ma RCW, Schmidt MI, Ramachandran A, Seino Y, Bennett PH, Oldenburg B, Gagliardino JJ, Luk AOY, Clarke PM, Ogle GD, Davies MJ, Holman RR, Gregg EW. The Lancet Commission on diabetes: using data to transform diabetes care and patient lives. The Lancet, 396, 2019–82 (2020) https://doi.org/10.1016/S0140-6736(20)32374-6.

Khan MAB, Hashim MJ, King JK, Govender RD, Mustafa H, Al Kaabi J. Epidemiology of Type 2 Diabetes - Global Burden of Disease and Forecasted Trends. J Epidemiol Glob Health, 10, 107–11 (2020) https://doi.org/10.2991/jegh.k.191028.001.

Pradeepa RG, Mohan V. Epidemiology of type 2 diabetes in India. Indian J Ophthalmol, 69, 2932–8 (2021) https://doi.org/10.4103/ijo.IJO_1627_21.

Zakir M, Ahuja N, Surksha MA, Sachdev R, Kalariya Y, Nasir M, Kashif M, Shahzeen F, Tayyab A, Khan MS moazzam, Junejo M, Manoj Kumar F, Varrassi G, Kumar S, Khatri M, Mohamad T. Cardiovascular Complications of Diabetes: From Microvascular to Macrovascular Pathways. Cureus, 15, e45835. (2023) https://doi.org/10.7759/cureus.45835.

Aderinto N, Olatunji G, Abdulbasit M, Ashinze P, Faturoti O, Ajagbe A, Ukoaka B, Aboderin G. The impact of diabetes in cognitive impairment: A review of current evidence and prospects for future investigations. Medicine, 102, e35557 (2023) https://doi.org/10.1097/MD.0000000000035557

Tomic D, Shaw JE, Magliano DJ. The burden and risks of emerging complications of diabetes mellitus. Nat Rev Endocrinol, 18, 525–39 (2022) https://doi.org/10.1038/s41574-022-00690-7

Zilliox LA, Chadrasekaran K, Kwan JY, Russell JW. Diabetes and cognitive impairment. Curr Diab Rep, 16, 1–11 (2016) https://doi.org/10.1007/s11892-016-0775-x

Momtaz YA, Hamid TA, Bagat MF, Hazrati M. The association between diabetes and cognitive function in later life. Curr Aging Sci, 12, 62–6 (2019) https://doi.org/10.2174/1874609812666190614104328

Zhao Q, Zhang Y, Liao X, Wang W. Executive function and diabetes: a clinical neuropsychology perspective. Front Psychol, 11, 2112 (2020) https://doi.org/10.3389/fpsyg.2020.02112

ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, Collins BS, Hilliard ME, Isaacs D, Johnson EL. 13. Older adults: standards of care in diabetes—2023. Diabetes Care, 46, S216–29 (2023) https://doi.org/10.2337/dc23-S013

You Y, Liu Z, Chen Y, Xu Y, Qin J, Guo S, Huang J, Tao J. The prevalence of mild cognitive impairment in type 2 diabetes mellitus patients: a systematic review and meta-analysis. Acta Diabetol, 58, 671–85 (2021) https://doi.org/10.1007/s00592-020-01648-9

Xue M, Xu W, Ou Y-N, Cao X-P, Tan M-S, Tan L, Yu J-T. Diabetes mellitus and risks of cognitive impairment and dementia: A systematic review and meta-analysis of 144 prospective studies. Ageing Res Rev, 55, 100944 (2019) https://doi.org/10.1016/j.arr.2019.100944

Subramanian M, Vasudevan K, Rajagopal A. Cognitive Impairment Among Older Adults With Diabetes Mellitus in Puducherry: A Community-Based Cross-Sectional Study. Cureus, 13, e12488 (2021) https://doi.org/10.7759/cureus.12488

Galicia-Garcia U, Benito-Vicente A, Jebari S, Larrea-Sebal A, Siddiqi H, Uribe KB, Ostolaza H, Martín C. Pathophysiology of type 2 diabetes mellitus. Int J Mol Sci, 21, 6275 (2020) https://doi.org/10.3390/ijms21176275

Zhang Q, Jin K, Chen B, Liu R, Cheng S, Zhang Y, Lu J. Overnutrition induced cognitive impairment: insulin resistance, gut-brain axis, and neuroinflammation. Front Neurosci, 16, 884579 (2022) https://doi.org/10.3389/fnins.2022.884579

Arnold SE, Arvanitakis Z, Macauley-Rambach SL, Koenig AM, Wang H-Y, Ahima RS, Craft S, Gandy S, Buettner C, Stoeckel LE. Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums. Nat Rev Neurol, 14, 168–81 (2018) https://doi.org/10.1038/nrneurol.2017.185

Więckowska-Gacek A, Mietelska-Porowska A, Wydrych M, Wojda U. Western diet as a trigger of Alzheimer’s disease: From metabolic syndrome and systemic inflammation to neuroinflammation and neurodegeneration. Ageing Res Rev, 70, 101397 (2021) https://doi.org/10.1016/j.arr.2021.101397

Zhang S, Zhang Y, Wen Z, Yang Y, Bu T, Bu X, Ni Q. Cognitive dysfunction in diabetes: abnormal glucose metabolic regulation in the brain. Front Endocrinol (Lausanne), 14, 1192602 (2023) https://doi.org/10.3389/fendo.2023.1192602

Gupta M, Pandey S, Rumman M, Singh B, Mahdi AA. Molecular mechanisms underlying hyperglycemia associated cognitive decline. IBRO Neurosci Rep, 14, 57–63 (2023) https://doi.org/10.1016/j.ibneur.2022.12.006

Feinkohl I, Price JF, Strachan MWJ, Frier BM. The impact of diabetes on cognitive decline: potential vascular, metabolic, and psychosocial risk factors. Alzheimers Res Ther, 7, 1–22 (2015) https://doi.org/10.1186/s13195-015-0130-5

Mushtaq G, H Greig N, A Khan J, A Kamal M. Status of acetylcholinesterase and butyrylcholinesterase in Alzheimer’s disease and type 2 diabetes mellitus. CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS & Neurological Disorders), 13, 1432–9 (2014) https://doi.org/10.2174/1871527313666141023141545

Shin SS, Dixon CE. Alterations in cholinergic pathways and therapeutic strategies targeting cholinergic system after traumatic brain injury. J Neurotrauma, 32, 1429–40 (2015) https://doi.org/10.1089/neu.2014.3445

Singh N, Yadav SS, Kumar S, Narashiman B. A review on traditional uses, phytochemistry, pharmacology, and clinical research of dietary spice Cuminum cyminum L. Phytotherapy Research, 35, 5007–30 (2021) https://doi.org/10.1002/ptr.7133

Golabi S, Mohammadi A, Chamkouri N. Investigation of anti-inflammatory effect of aqueous extract of Cuminum cyminum L. by formalin inflammatory model in male rats. Journal of Medicinal Plants, 18, 236–46 (2019) https://doi.org/10.29252/jmp.4.72.S12.236

Mnif S, Aifa S. Cumin (Cuminum cyminum L.) from traditional uses to potential biomedical applications. Chem Biodivers, 12, 733–42 (2015) https://doi.org/10.1002/cbdv.201400305

Shaheen HM, Bindebe SMLKB, Nyemb JN, Abdou JP, George J, Patil VR, Segueni N, Batiha GE-S. Ethnomedicinal uses, phytochemical, pharmacological and pharmacokinetics properties of Cumin (Cuminum cyminum). The Journal of Phytopharmacology, 12, 315–25 (2023) https://doi.org/10.31254/phyto.2023.12507

Dhandapani S, Subramanian VR, Rajagopal S, Namasivayam N. Hypolipidemic effect of Cuminum cyminum L. on alloxan-induced diabetic rats. Pharmacol Res, 46, 251–5 (2002) https://doi.org/10.1016/S1043-6618(02)00131-7

Morales-Delgado N, Popović N, De la Cruz-Sánchez E, Caballero Bleda M, Popović M. Time-of-Day and Age Impact on Memory in Elevated Plus-Maze Test in Rats. Front Behav Neurosci, 12, 304 (2018) https://doi.org/10.3389/fnbeh.2018.00304.

Kameyama T, Nabeshima T, Kozawa T. Step-down-type passive avoidance- and escape-learning method: Suitability for experimental amnesia models. J Pharmacol Methods, 16, 39–52 (1986) https://doi.org/https://doi.org/10.1016/0160-5402(86)90027-6.

Morris RGM. Spatial localization does not require the presence of local cues. Learn Motiv, 12, 239–60 (1981) https://doi.org/10.1016/0023-9690(81)90020-5

Othman MZ, Hassan Z, Has ATC. Morris water maze: a versatile and pertinent tool for assessing spatial learning and memory. Exp Anim, 71, 264–80 (2022) https://doi.org/10.1538/expanim.21-0120

Ellman GL, Courtney KD, Andres V, Featherstone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol, 7, 88–95 (1961) https://doi.org/https://doi.org/10.1016/0006-2952(61)90145-9.

Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem, 95, 351–8 (1979) https://doi.org/https://doi.org/10.1016/0003-2697(79)90738-3.

Ellman GL. Tissue sulfhydryl groups. Arch Biochem Biophys, 82, 70–7 (1959) https://doi.org/10.1016/0003-9861(59)90090-6.

McCrimmon RJ. Consequences of recurrent hypoglycaemia on brain function in diabetes. Diabetologia, 64, 971–7 (2021) https://doi.org/10.1007/s00125-020-05369-0

Burgos-Morón E, Abad-Jiménez Z, Martinez de Maranon A, Iannantuoni F, Escribano-López I, López-Domènech S, Salom C, Jover A, Mora V, Roldan I. Relationship between oxidative stress, ER stress, and inflammation in type 2 diabetes: the battle continues. J Clin Med, 8, 1385 (2019) https://doi.org/10.3390/jcm8091385

Petersen MC, Shulman GI. Mechanisms of Insulin Action and Insulin Resistance. Physiol Rev, 98, 2133–223 (2018) https://doi.org/10.1152/physrev.

Jagtap AG, Patil PB. Antihyperglycemic activity and inhibition of advanced glycation end product formation by Cuminum cyminum in streptozotocin induced diabetic rats. Food and chemical toxicology, 48, 2030–6 (2010) https://doi.org/10.1016/j.fct.2010.04.048

Mohamed DA, Hamed IM, Fouda KA. Antioxidant and anti-diabetic effects of cumin seeds crude ethanol extract. J Biol Sci, 18, 251–9 (2018) https://doi.org/10.3923/jbs.2018.251.259

Patil SB, Takalikar SS, Joglekar MM, Haldavnekar VS, Arvindekar AU. Insulinotropic and β-cell protective action of cuminaldehyde, cuminol and an inhibitor isolated from Cuminum cyminum in streptozotocin-induced diabetic rats. British journal of nutrition, 110, 1434–43 (2013) https://doi.org/10.1017/S0007114513000627

Wang X, Fang H, Xu G, Yang Y, Xu R, Liu Q, Xue X, Liu J, Wang H. Resveratrol Prevents Cognitive Impairment in Type 2 Diabetic Mice by Upregulating Nrf2 Expression and Transcriptional Level. Diabetes, Metabolic Syndrome and Obesity, 13, 1061–75 (2020) https://doi.org/10.2147/DMSO.S243560.